Literature DB >> 12000691

Nasopharyngeal carcinoma: treatments and outcomes in the 20th century.

R F Mould1, T H P Tai.   

Abstract

Nasopharyngeal carcinoma (NPC), although rare in Europe and North America, is not uncommon in parts of Asia such as southern China and Hong Kong. Consequently, very few oncologists in the Western world have extensive experience in treating this neoplasm. Treatment using external beam therapy and/or brachytherapy evolved greatly during the 20th century and is still evolving, particularly with the use of adjunctive chemotherapy regimes. Diagnosis of NPC has also improved with the availability of CT and MRI. This worldwide review is divided into historical, transitional and modern eras, with the latter concerning 1971-2000. Currently, the most controversial aspects of NPC are recommendations for treatment of recurrent disease and the role of chemotherapy in the overall framework of treatment. Comparison of results from different centres is not possible without an understanding of the various staging systems that are, and have been, used; a comparison is given in this review. In the future, early diagnosis, adequate radiation dose to the primary with boost to bulky disease, and regular follow-up with biopsy of any suspicious residual or recurrent disease, are likely to become key issues to improve outcome. Also, apart from direct/indirect nasopharyngoscopy, the role of follow-up CT needs to be studied for early detection of residual or recurrent disease. More clinical trials on chemo-radiation are also required, in order to study optimum doses and agents.

Entities:  

Mesh:

Year:  2002        PMID: 12000691     DOI: 10.1259/bjr.75.892.750307

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  12 in total

Review 1.  Recurrent nasopharyngeal carcinoma: a clinical dilemma and challenge.

Authors:  Tao Xu; J Tang; M Gu; L Liu; W Wei; H Yang
Journal:  Curr Oncol       Date:  2013-10       Impact factor: 3.677

2.  A phase II study evaluating the safety and efficacy of an adenovirus-ΔLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma.

Authors:  W K Chia; W-W Wang; M Teo; W M Tai; W T Lim; E H Tan; S S Leong; L Sun; J J Chen; S Gottschalk; H C Toh
Journal:  Ann Oncol       Date:  2011-08-04       Impact factor: 32.976

3.  A retrospective study of salvage surgery for recurrent nasopharyngeal carcinoma.

Authors:  Xue Bian; Hui Chen; Lianming Liao
Journal:  Int J Clin Oncol       Date:  2011-06-29       Impact factor: 3.402

4.  Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma.

Authors:  Chrystal U Louis; Karin Straathof; Catherine M Bollard; Sravya Ennamuri; Claudia Gerken; Teresita T Lopez; M Helen Huls; Andrea Sheehan; Meng-Fen Wu; Hao Liu; Adrian Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop; Stephen Gottschalk
Journal:  J Immunother       Date:  2010 Nov-Dec       Impact factor: 4.456

5.  IAP-1 promoted cisplatin resistance in nasopharyngeal carcinoma via inhibition of caspase-3-mediated apoptosis.

Authors:  Xiangwan Miao; Zeyi Deng; Siqi Wang; Huanhuan Weng; Xinting Zhang; Hailiang Li; Huifen Xie; Juan Zhang; Ying Zhong; Bohui Zhang; Quanming Li; Minqiang Xie
Journal:  Am J Cancer Res       Date:  2021-03-01       Impact factor: 6.166

6.  Are dual-phase 18F-FDG PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and loco-regional nodes?

Authors:  Tzu-Chen Yen; Yu-Chen Chang; Sheng-Chieh Chan; Joseph Tung-Chieh Chang; Ching-Han Hsu; Kun-Ju Lin; Wuu-Jyh Lin; Ying-Kai Fu; Shu-Hang Ng
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-12-30       Impact factor: 9.236

7.  Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients.

Authors:  Chrystal U Louis; Karin Straathof; Catherine M Bollard; Claudia Gerken; M Helen Huls; M Victoria Gresik; Meng-Fen Wu; Heidi L Weiss; Adrian P Gee; Malcolm K Brenner; Cliona M Rooney; Helen E Heslop; Stephen Gottschalk
Journal:  Blood       Date:  2008-10-29       Impact factor: 22.113

8.  Human papillomavirus and Epstein-Barr virus in nasopharyngeal carcinoma in a low-incidence population.

Authors:  Snjezana Dogan; Matthew L Hedberg; Robert L Ferris; Tanya J Rath; Adel M Assaad; Simion I Chiosea
Journal:  Head Neck       Date:  2013-06-18       Impact factor: 3.147

9.  Trends in the survival of patients with nasopharyngeal carcinoma between 1976 and 2005 in Sihui, China: a population-based study.

Authors:  Qing Liu; Jin-Ou Chen; Qi-Hong Huang; Yan-Hua Li
Journal:  Chin J Cancer       Date:  2012-12-13

10.  Functional inactivation of EBV-specific T-lymphocytes in nasopharyngeal carcinoma: implications for tumor immunotherapy.

Authors:  Jiang Li; Xue-hui Zeng; Hao-yuan Mo; Ulrika Rolén; Yan-fang Gao; Xiao-shi Zhang; Qiu-yan Chen; Li Zhang; Mu-sheng Zeng; Man-zhi Li; Wen-lin Huang; Xiao-ning Wang; Yi-xin Zeng; Maria G Masucci
Journal:  PLoS One       Date:  2007-11-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.